Krystal Biotech, Inc. (NASDAQ:KRYS) Sees Significant Drop in Short Interest

Krystal Biotech, Inc. (NASDAQ:KRYS) saw a significant drop in short interest in the month of January. As of January 15th, there was short interest totalling 3,370,000 shares, a drop of 8.9% from the December 31st total of 3,700,000 shares. Based on an average daily volume of 247,300 shares, the short-interest ratio is presently 13.6 days.

Insider Transactions at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction on Friday, December 13th. The stock was sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the completion of the sale, the insider now directly owns 1,475,882 shares in the company, valued at approximately $243,195,835.96. This represents a 1.67 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 14.10% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Krystal Biotech

Institutional investors and hedge funds have recently made changes to their positions in the business. TimesSquare Capital Management LLC lifted its stake in Krystal Biotech by 39.1% in the fourth quarter. TimesSquare Capital Management LLC now owns 158,868 shares of the company’s stock valued at $24,888,000 after buying an additional 44,646 shares during the period. AlphaCentric Advisors LLC bought a new stake in shares of Krystal Biotech in the 4th quarter valued at $231,000. Principal Financial Group Inc. lifted its position in shares of Krystal Biotech by 3.1% during the 4th quarter. Principal Financial Group Inc. now owns 123,453 shares of the company’s stock valued at $19,340,000 after acquiring an additional 3,727 shares during the period. State of New Jersey Common Pension Fund D boosted its stake in Krystal Biotech by 19.3% during the fourth quarter. State of New Jersey Common Pension Fund D now owns 11,803 shares of the company’s stock worth $1,849,000 after acquiring an additional 1,910 shares in the last quarter. Finally, Certuity LLC acquired a new stake in Krystal Biotech in the fourth quarter worth $214,000. Institutional investors own 86.29% of the company’s stock.

Krystal Biotech Stock Down 1.9 %

NASDAQ KRYS opened at $156.71 on Monday. The company has a market capitalization of $4.51 billion, a price-to-earnings ratio of 88.48 and a beta of 0.84. Krystal Biotech has a twelve month low of $107.50 and a twelve month high of $219.34. The stock has a fifty day simple moving average of $165.65 and a 200 day simple moving average of $179.28.

Krystal Biotech (NASDAQ:KRYS) last posted its quarterly earnings data on Monday, November 4th. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.84 by $0.07. The company had revenue of $83.84 million during the quarter, compared to analysts’ expectations of $82.94 million. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. Krystal Biotech’s revenue for the quarter was up 879.9% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.67) earnings per share. Research analysts expect that Krystal Biotech will post 3.22 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on KRYS shares. Chardan Capital reaffirmed a “buy” rating and issued a $212.00 price objective on shares of Krystal Biotech in a research note on Wednesday, December 18th. Citigroup upped their price target on shares of Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Finally, HC Wainwright restated a “buy” rating and set a $221.00 price objective on shares of Krystal Biotech in a research report on Wednesday, December 18th. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $206.67.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).